title: [Management of toxicities due to anti-angiogenic treatment of metastatic renal carcinoma].
abstract: Important advances have been achieved in the treatment of metastatic renal cell carcinoma in the last few years with the targeted therapy. The consequences on the physiological microvasculature could be at the origin of the adverse effects. It seems important for the clinician to know the physiopathology and the management of these toxicities.
authors.affiliation: Service d'Urologie, Université Paris Descartes, France. arnaud.mejean@nck.aphp.fr
authors.forename: A
authors.initials: A
authors.lastname: Méjean
authors.forename: T
authors.initials: T
authors.lastname: Lebret
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary*; D006801:Humans; D006973:Hypertension / Q000139:chemically induced / Q000628:therapy; D007680:Kidney Neoplasms / Q000473:pathology*
chemical_list: D020533:Angiogenesis Inhibitors